Oncology Venture participates on investor meetings tomorrow and on Friday
Hørsholm, Denmark, January 17th, 2018 – Oncology Venture Sweden AB (”Oncology Venture”) will participate on investor meetings in Malmö and Stockholm on January 18-19th, 2018. CEO Peter Buhl Jensen will present the company and its plans for the future. The investor meetings are free of charge to attend and light refreshments will be served. Please see below for more information concerning the investor meetings and registration to the events.
|Date and time||Organiser||Place||Registration|
|January 18th11.30 – 13.00||Sedermera Fondkommission||Börshuset,Skeppsbron 2,211 20 Malmö||Please register here to attend http://www.sedermera.se/evenemang/2018-01-18/investerarlunch-malmo-181|
|January 19th 12.10 – 12.30||Aktiespararna||Scandic Klara,Slöjdgatan 7,111 57 Stockholm||Please register here to attend https://www.aktiespararna.se/aktiviteter/valkommen-till-investerardagen-19-januari-pa-hotell-scandic-klara-hotorget|
For further information, please contact:
|Ulla Hald Buhl,
COO andChief IR & Communications
Mobile: +45 2170 1049
|or||Peter Buhl Jensen,
Mobile: +45 21 60 89 22
About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction - DRP® - in order to significantly increase the probability of success in clinical trials. DRP® has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients' tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
The current product portfolio: LiPlaCis® for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 - an immuno-oncology product for Multiple Myeloma.
Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women's cancers with a pipeline of three promising phase 2 product candidates. OV-SPV 2 is a Danish company that shall test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor. Oncology Venture currently holds 92 percent of the shares in 2X Oncology Inc. and 40 percent of the shares in OV-SPV 2.